IMARC Group, a leading market research company, has recently releases report titled “Hematologic Malignancies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” The study provides a detailed analysis of the industry, including the global hematologic malignancies market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights

How big is the hematologic malignancies market?

The global hematologic malignancies market size reached US$ 55.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 93.2 Billion by 2028, exhibiting a growth rate (CAGR) of 8.4% during 2023-2028.

What are hematologic malignancies?

Hematologic malignancies refer tomedical conditions related to blood-producing cells, including lymphoma, multiple myeloma, leukemia, etc. The blood-producing cells comprise platelets for wound clotting, white blood cells (WBCs) for immune protection, and red blood cells (RBCs) to carry oxygen. Hematologic malignancies can be diagnosed using tests, such as cytogenetics, microscopy, polymerase chain reaction (PCR), flow cytometry, immunophenotyping, fluorescence in situ hybridization (FISH), gene expression profiling, etc. At present, several drugs, including histone deacetylase inhibitors, antitumor antibiotics, Janus kinase (JAK) inhibitors, etc., are available for treatment based on diagnostic tests.

Request for a sample copy of this report: https://www.imarcgroup.com/hematologic-malignancies-market/requestsample

What are the growth prospects and trends in the hematologic malignancies industry?

The rising incidences of acute myeloid leukemia (AML) are driving the hematologic malignancies market. Furthermore, various advancements in immunohistochemistry (IHC) and accurate diagnosis of hematologic malignancies by exposing tissue samples to numerous antibodies, are fueling the market growth. Additionally, surgical therapy is available for tissue diagnosis and treatment of lymphoma complications, such as obstruction, perforation, stricture, etc. Moreover, multiple label expansions of premium-priced agents, including brexucabtagene autolyse and CAR T-cell therapies, and the launch of several novel therapies are bolstering the product demand. Apart from this, ongoing research and development activities to introduce advanced drugs for patients with complex hematologic malignancies are expected to fuel the market in the coming years.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Type:

• Leukemia
• Lymphoma
• Multiple Myeloma
• Others

Breakup by Therapy:

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Stem Cell Transplantation
• Others

Breakup by End User:

• Hospitals
• Diagnostics Centers
• Research Centers
• Others

Breakup by Region:

• North America (U.S. & Canada)
• Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
• Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
• Latin America (Brazil, Mexico)
• Middle East & Africa

Who are the key players operating in the industry?

The report covers the major market players including:

• AbbVie Inc.
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co. Inc
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: [email protected]

Follow us on Twitter: @imarcglobal